Clinical Trial Update: Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 pilot trial testing denosumab, a RANKL antibody, in patients with osteogenesis imperfecta.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteogenesis Imperfecta

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: University of Cologne | Conditions: Osteogenesis Imperfecta | Phase 2 | Status: COMPLETED